Cervical Cancer Screening Webinar
-
Upload
fernando-gonzalez-peruggi -
Category
Documents
-
view
218 -
download
0
Transcript of Cervical Cancer Screening Webinar
-
8/19/2019 Cervical Cancer Screening Webinar
1/53
CERVICAL CANCERSCREENING
-
8/19/2019 Cervical Cancer Screening Webinar
2/53
MARCH 15, 2012
• The USPSTF and the ACS (inconjunction with ASCCP and ASCP)released updated cervical cancerscreening recommendations
• Not a coincidence
• Independently developed• Remarkably similar
conclusions/guidelines
-
8/19/2019 Cervical Cancer Screening Webinar
3/53
-
8/19/2019 Cervical Cancer Screening Webinar
4/53
CERVICAL CANCER
• Histologic types
• Squamous cell• 70% of all cases (primary target of
cytological screening)
• Arises at squamocolumnar junction(transformation zone)
• Primary target of cytology screening
• Adenocarcinoma• ~18%
• Mixed adenosquamous and other
-
8/19/2019 Cervical Cancer Screening Webinar
5/53
A reminder: squamocolumnar junction
-
8/19/2019 Cervical Cancer Screening Webinar
6/53
CERVICAL CANCERMORTALITY (PER 100,000)
White Non-white Combined
1950(unadjusted)
10.2 18.0
2007(adjusted)
2.2 4.3 2.4
This dramatic decline has beenattributed to the implementation and
dissemination of screening.
-
8/19/2019 Cervical Cancer Screening Webinar
7/53
CERVICAL CANCERINCIDENCE & MORTALITY
-
8/19/2019 Cervical Cancer Screening Webinar
8/53
BURDEN OF ILLNESS
• SEER data:
• “It is estimated that 12,710 women willbe diagnosed with and 4,290 women
will die of cancer of the cervix uteri in 2011.”
• For comparison, for every woman whowill die of cervical cancer
• 5 will die of colon cancer
• 8 will die of breast cancer
• 15 will die of lung cancer
-
8/19/2019 Cervical Cancer Screening Webinar
9/53
INADEQUATE SCREENING
• About half of all cervical cancer deathsare in women who have not beenscreened or who have had incompletefollow-up to screening and treatment
• If we could assure adequate screeningof the entire population, the residualpreventable burden would be small
• What goals should we have for achange in prevention strategy,whether immunization or a change inscreening approach?
-
8/19/2019 Cervical Cancer Screening Webinar
10/53
POSSIBLE GOALS FOR NEWCERVICAL CANCER PREVENTION
STRATEGIES (INCLUDING IMMUNIZATION)
• Further reduction in mortality
• Caveat:the elimination of cervicalcancer and/or cervical cancermortality is not a realistic goal ofscreening
• Reduction in the burden and/orharms of screening and treatmentof screen-detected disease
-
8/19/2019 Cervical Cancer Screening Webinar
11/53
Draft University of
Missouri
Department of
Family Medicine
updated clinicalalgorithm for
cervical cancer
screening
http://fcm-algo.umh.edu/Algorithms/CCS.htm
-
8/19/2019 Cervical Cancer Screening Webinar
12/53
Screening
Evaluation ofabnormal
screen
Follow up post
colposcopy
-
8/19/2019 Cervical Cancer Screening Webinar
13/53
SCREENING
-
8/19/2019 Cervical Cancer Screening Webinar
14/53
SCREENING
-
8/19/2019 Cervical Cancer Screening Webinar
15/53
SCREENING
-
8/19/2019 Cervical Cancer Screening Webinar
16/53
HPV INFECTION
• “It is well recognized that infectionwith oncogenic HPV types is anecessary, although not sufficient,
cause of virtually all cervicalcancer.25 “
• Results from a large international
collection of cervical tumorspecimens revealed the presence ofHPV DNA in 99.7 percent of cases.3
http://preview.ncbi.nlm.nih.gov/bookshelf/booktest/br.fcgi?book=es86&part=references.rl1http://preview.ncbi.nlm.nih.gov/bookshelf/booktest/br.fcgi?book=es86&part=references.rl1http://preview.ncbi.nlm.nih.gov/bookshelf/booktest/br.fcgi?book=es86&part=references.rl1http://preview.ncbi.nlm.nih.gov/bookshelf/booktest/br.fcgi?book=es86&part=references.rl1
-
8/19/2019 Cervical Cancer Screening Webinar
17/53
HPV INFECTION: NATURALHISTORY
• From HPV infection to cervicalcancer
• HPV transmission,• Acute HPV infection,
• Persistent HPV infection leading toprecancerous changes, and
• ICC.45
http://preview.ncbi.nlm.nih.gov/bookshelf/booktest/br.fcgi?book=es86&part=references.rl1http://preview.ncbi.nlm.nih.gov/bookshelf/booktest/br.fcgi?book=es86&part=references.rl1
-
8/19/2019 Cervical Cancer Screening Webinar
18/53
HPV TRANSMISSION
• Primarily as a result of skin-to-skinor mucosa-to-mucosa contact
-
8/19/2019 Cervical Cancer Screening Webinar
19/53
HPV INFECTION ANDPERSISTENCE
• A high proportion of sexually activewomen become infected with HPV,but only a small proportion of HPVinfections become persistent
• 91 percent of prevalent HPVinfections clear within 24 months
(including infections with high risksubtypes)
-
8/19/2019 Cervical Cancer Screening Webinar
20/53
PREVALENCE OF HPVINFECTION
-
8/19/2019 Cervical Cancer Screening Webinar
21/53
WHY NOT SCREEN BEFOREAGE 21?
• Cervical cancer is rare in theyounger age group
Per 100,000 women
-
8/19/2019 Cervical Cancer Screening Webinar
22/53
WHY NOT SCREEN BEFOREAGE 21?
• HPV infection is common andresults in transient abnormalities ofthe cervix
• Detection and Rx of thoseabnormalities leads to harm
-
8/19/2019 Cervical Cancer Screening Webinar
23/53
WHAT ABOUT SEXUALHISTORY?
• Young women with multiple sexualpartners are the most susceptible tothe harms of screening
• The possibility of benefit isvanishingly close to zero
• Just say no to screening for cervicalcancer before age 21.
-
8/19/2019 Cervical Cancer Screening Webinar
24/53
SCREENING
-
8/19/2019 Cervical Cancer Screening Webinar
25/53
SCREENING INTERVAL FOR
CYTOLOGY IN WOMEN AGE 21-65
• RCTs of screening programs atdifferent intervals never exist
• e.g. no one has done an RCTcomparing colonoscopy for coloncancer screening every 5 years to
every 10 years or 20 tears (decided toleave in the typo)
• Task Force has used modeling
-
8/19/2019 Cervical Cancer Screening Webinar
26/53
WHAT OUTCOME,PARTICULARLY FOR HARMS?
• False positives
• Colposcopies
• CIN 2-3
• Cancer cases, cancer deaths
-
8/19/2019 Cervical Cancer Screening Webinar
27/53
HARMS:COLPOSCOPIES
• Pain, bleeding
• Sentinel measure for downstream
harms• Similar to using number of
colonoscopies as sentinel measure ofharm in modeling of colon cancerscreening
-
8/19/2019 Cervical Cancer Screening Webinar
28/53
HARMS: OVER-DIAGNOSIS
• CIN2 can/does regress – over-diagnosis and over-treatment arereal risks
• CIN3 can also regress
• Standard of care currently to Rx all
CIN2+
-
8/19/2019 Cervical Cancer Screening Webinar
29/53
TREATMENT OF CIN2+
• Common treatments include LEEP orcervical conization
• Short term harms of pain (67%),
bleeding (87%), discharge (63%)• Increased risk of adverse pregnancy
outcomes
• Perinatal mortality, preterm delivery,low birth weight
• Evidence on specific procedures isincomplete and retrospective
MODEL: ENORMOUSLY
-
8/19/2019 Cervical Cancer Screening Webinar
30/53
MODEL: ENORMOUSLYCOMPLICATED – EVEN IF YOU LIKE
MATH
-
8/19/2019 Cervical Cancer Screening Webinar
31/53
CYTOLOGY STARTING AGE 21,FOLLOWED FOR LIFE (PER 1000)
Q1 Q2 Q3 q5
False
positives
951 515 350 214
Colposcopy 1931 1084 758 483
CIN 2-3 91 88 80 66
Cancer
cases
2.5 5.8 8.5 12.7
Cancer
deaths
0.3 0.9 1.5 2.7
Quote from Task Force member:
“All models are wrong, some are
useful.”
-
8/19/2019 Cervical Cancer Screening Webinar
32/53
OBSERVATIONAL STUDY
• Lancet Oncology, vol 12, July 2011
• “Cervical cancer risk for womenundergoing concurrent testing forhuman papillomavirus and cervicalcytology: a population based studyin routine clinical practice”
• Katki et al followed 313,818 womenin Kaiser Permanente NorthernCalifornia
-
8/19/2019 Cervical Cancer Screening Webinar
33/53
OBSERVATIONAL STUDY ONINCIDENCE
• 319,177 (96.2%) of women hadnormal Pap at baseline
• CIN3+ at:• 3 years 0.17%,
• 5 years 0.36%
• Risk of invasive cancer at five years
after normal cytology was 7.5 per100,000 women (0.0075%)
-
8/19/2019 Cervical Cancer Screening Webinar
34/53
SCREENING INTERVAL FORCYTOLOGY IN WOMEN AGE 21-65
• Cytology every 3 years demonstratesa good balance of benefits and harms
• “Pap smears every three years aresafe and effective at reducing cervicalcancer, while minimizing the risks offalse positive results and the harms
associated with treating disease thatwill go away without treatment.”
-
8/19/2019 Cervical Cancer Screening Webinar
35/53
SCREENING
-
8/19/2019 Cervical Cancer Screening Webinar
36/53
WHAT IS THE ROLE FOR HPVTESTING IN SCREENING?
-
8/19/2019 Cervical Cancer Screening Webinar
37/53
RECALL: PREVALENCE OFHPV INFECTION
-
8/19/2019 Cervical Cancer Screening Webinar
38/53
HPV SCREENING BEFOREAGE 30
• Recommend against
• Prevalence is high, therefore falsepositive rate is high
• False positive in this context does notmean the test is positive in someonewho does not have HPV
• False positive means identifying
someone “in need of intervention” toprevent cervical cancer who does notneed that intervention because herdisease will regress spontaneously
Just say no to screening
for cervical cancer withHPV before age 30.
-
8/19/2019 Cervical Cancer Screening Webinar
39/53
HPV SCREENING FOR CERVICALCANCER FOR AGE > 30 YEARS
• Multiple studies of varied designdemonstrate that HPV testing is…
• More sensitive than cytology forCIN2+
• Less specific than cytology
• The Task Force had the challenge of
being “moderately certain” aboutthe balance of benefits and harms.
-
8/19/2019 Cervical Cancer Screening Webinar
40/53
RCTS OF HPV SCREENINGFOR CERVICAL CANCER
• EPC reviewed and presented theresults of 6 European RCTs thatincluded HPV in some way in the
experimental group• Inconsistent design, varying
protocols, incomplete reporting andperhaps most importantlyincomplete follow-up through tworounds of testing
-
8/19/2019 Cervical Cancer Screening Webinar
41/53
DRAFT RECOMMENDATION
• Insufficient evidence to determinethe balance of benefits and harmsof HPV screening
-
8/19/2019 Cervical Cancer Screening Webinar
42/53
POST DRAFT
• Two important publications
• Completed follow-up of the secondround of the RCT in the Netherlands
• Kaiser observational data notedearlier in presentation
-
8/19/2019 Cervical Cancer Screening Webinar
43/53
POBASCAM
• 44,938 women age 30-56 randomizedto screening with conventionalcytology vs. co-testing with HPV andconventional cytology
• Round two testing in five years – bothgroups received co-testing
• Complex protocol for referral forcolposcopy – does not reflect currentstandard of care in the US
• e.g. immediate referral only for HSIL
-
8/19/2019 Cervical Cancer Screening Webinar
44/53
POBASCAM RESULTS
Cumulative CIN2
Cytology round one
127
Co-testing round one
168
Cumulative CIN3 252 243
Round one cancer 6 12
Round two cancer 14 4
Cumulative cancer 20 16
Recall denominator in each group ~20,000
-
8/19/2019 Cervical Cancer Screening Webinar
45/53
POBASCAM APPLICABLE TOUS?
• We are more aggressive in use ofcolposcopy, so detection of CIN2+likely to be higher
• Safe to conclude that co-testingevery five years as good as(better?) than cytology every five
years in an RCT
• Reported harms (CIN2) modest
-
8/19/2019 Cervical Cancer Screening Webinar
46/53
CYTOLOGY EVERY 3 YEARS VSCO-TESTING EVERY 5 YEARS
• Kaiser observational data
• Further exploration in the model to
try to fill in gaps in evidence fromPOBASCAM and Kaiser
-
8/19/2019 Cervical Cancer Screening Webinar
47/53
KAISER DATA
• Cumulative incidence of CIN3+ the same(0.17%) …
• three years after normal cytology and
• five years after double negative co-testing
• Other analyses confirm increased
sensitivity and decreased specificity ofHPV testing relative to cytology
• Did not report total colposcopies
-
8/19/2019 Cervical Cancer Screening Webinar
48/53
MODEL DATA
False
positives
Colpos-
copies
CIN2-3 Cancers Cancer
deaths
Cytology
q3 years
350 758 80 8.5 1.55
Cytologyq3 years
until age
30 then
co-testing
q5 years
255 575 84 7.44 1.35
Note: model assumed women with
normal colposcopy immediately returned
to usual screening
WHAT IS THE ROLE FOR HPV
-
8/19/2019 Cervical Cancer Screening Webinar
49/53
WHAT IS THE ROLE FOR HPVTESTING IN SCREENING?
-
8/19/2019 Cervical Cancer Screening Webinar
50/53
SCREENING
-
8/19/2019 Cervical Cancer Screening Webinar
51/53
AGE 65 YEARS OR OLDER
• Potential for benefit in thoseadequately screened in the pastwhose screening tests are normal is
very low, potential for harm at leastsmall
• Note women who have had CIN2+should continue to be screened for 20
years• Consider screening women who do nothave a history of adequate screening
-
8/19/2019 Cervical Cancer Screening Webinar
52/53
TWO IMPORTANT CHANGES
• USPSTF did not addressmanagement of abnormal results –but ACS/ASCCP did make two
specific recommedations
• ASCUS/HPV negative – Rx as normal
• Negative Cytology/+HPV
• Repeat in one year and colpo if either ispositive, or…
• Test for HPV 16/18 and colpo if positive
-
8/19/2019 Cervical Cancer Screening Webinar
53/53
QUESTIONS?